Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Farrar, Michelle
REACH CDM, NCT03692312: Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy	Completed	2/3	56	Europe, Canada, US, RoW	Tideglusib, Placebo	AMO Pharma Limited	Congenital Myotonic Dystrophy	04/23	04/23
REACH CDM X, NCT05004129: Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy	Recruiting	2/3	76	Canada, US, RoW	Tideglusib	AMO Pharma Limited	Congenital Myotonic Dystrophy	03/25	03/25
Horrigan, Joseph P
REACH CDM, NCT03692312: Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy	Completed	2/3	56	Europe, Canada, US, RoW	Tideglusib, Placebo	AMO Pharma Limited	Congenital Myotonic Dystrophy	04/23	04/23
REACH CDM X, NCT05004129: Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy	Recruiting	2/3	76	Canada, US, RoW	Tideglusib	AMO Pharma Limited	Congenital Myotonic Dystrophy	03/25	03/25
Holland, Sandra
REACH CDM, NCT03692312: Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy	Completed	2/3	56	Europe, Canada, US, RoW	Tideglusib, Placebo	AMO Pharma Limited	Congenital Myotonic Dystrophy	04/23	04/23